Probiotic market size of nearly 100 billion Coto bio-with star strains to create the future

, the global probiotic market will be worth about 40 billion euros (about 300 billion yuan) in 2019, according to the World Health Agency. China's probiotic market is growing at an average annual rate of about 15%, and is expected to reach nearly 90 billion yuan market size by 2022, and probiotics are expected to become the next big health market.on this opportunity-filled track, Chinese companies are gradually appearing in everyone's sights. On July 27, 2020, the high-profile representative of China's intestinal industry innovation enterprises, "the first stock of probiotics" - Koto Bio (300858) officially landed on the A-share Shenzhen Stock Exchange GEM, officially opened the Chinese probiotic enterprise deer-by-deer market.Koto Bio is committed to building the world's largest library of bacteriadata show that Koto Bio was founded in 2003, is committed to the research and development, production and sale of probiotic lactic acid bacteria and their products, compound food additives, and to provide customers with a complete range of product solutions. But as early as 2001, the founders of Coto Bio officially launched the species program. The program follows the ancient trade route and fermented milk transmission channels to carry out a global collection, separation and protection of strains, aimed at collecting and protecting Lactobacillus, Bifidobacteria and other lactobacillus resources. Since the launch of the species program, Koto Bio has collected more than 6,000 samples of naturally fermented food, baby faeces and breast milk from pristine, non-polluting areas, and isolated, collected and maintained more than 20,000 strains of Lactobacillus and Bifidobacteria.2018, Koto Bio has set new goals to build the world's largest repository of bacteria. Through international cooperation, Koto Bio plans to further isolate more lactic acid bacteria from natural fermented dairy products in Central Asia, North Asia, the Middle East, Africa and Europe, and is expected to complete the establishment of a strain bank by 2022. Bringing together global strain resources, in-depth industrial transformation in China, and the establishment of Chinese's unique intellectual property rights, product line and solutions strongly support the core strategy of Koto Bio.Breaking the monopoly of Coto Bio to create a Chinese probiotic star strain The most well-known strain of Koto Bio is Cheese Lactobacillus Zhang, which was extracted from natural fermented acid horse milk from xilin Guole Prairie in 2002, and it is one of the earliest isolated lactic acid bacteria of Koto Biology. After successful isolation, Koto Bio sequenced the strain genome, becoming the first lactic acid bacteria in China to complete genome-wide sequencing.the discovery of this strain, naturally can not be separated from the Chinese probiotic pioneers, Coto Bio chief scientist Professor Zhang Peace. And the cheesecella Zhang, in the "Zhang" is Professor Zhang Peace's last name "Zhang"., there are also several well-known probiotics associated with the discovery of human names. For example, the cheese-lactobacillus daita strain, which is owned by Ledo, was isolated and cultured by Professor Daita in 1930 at Kyoto University; For example, the well-known LGG strain of Lactobacillus lactobacillus (LGG), which was isolated from the healthy human body in the United States in 1983 by Professor Gorbach and Professor Goldin, is taken from the "G" in the names of the two professors.the strains that may have been named after them all have extraordinary "bacterial transport", Ando Bio has filed 16 patents for inventions around Bacillus Cheese Zhang and published more than 170 papers. The strain has been found to have many benefits in a series of studies and has been fully used in many products. It is the "signature" strain of Koto bio, and also becomes the representative of the Chinese strain of the internationally renowned strain.In fact, the obvious strains owned by Coto Bio, represented by Bacillus Cheese Zhang, Lactobacillus C. V9, Plant Lactobacillus P-8, Lactobacillus Probio-M8 and Lactobacillus Saccharide, have accumulated similar foundation, clinical research data and evidence to well-known strains abroad. Especially in the recent years when the research of intestinal microbiome is booming, the research and industrialization application of related strains have even surpassed the trend.years, with the implementation of the "Healthy China 2030" program outline, the country is vigorously promoting the development of the health industry, and the arrival of the new crown pneumonia epidemic, but also let everyone more to look at the importance of health. Originating from nature, passing health, as the first stock of Chinese probiotics, Koto Bio will further rely on China's capital market, play its own original strains and processing technology advantages, to basic research and adhere to science and technology as the first productive force of continuous efforts to innovate, carefully do a good job of products, for healthy China refueling.